Librela

Bedinvetmab anti-NGF monoclonal antibody for osteoarthritis pain in dogs; monthly injection. Anti-NGF monoclonal antibody (bedinvetmab). Mechanism: fully caninized IgG2 monoclonal antibody that specifically binds and neutralizes nerve growth factor (NGF) → prevents NGF binding to TrkA (tropomyosin receptor kinase A) and p75NTR receptors → reduces central and peripheral sensitization and pain signaling in osteoarthritis. Monthly SQ injection. Key information Bedinvetmab — anti-NGF monoclonal antibody for canine OA pain. Refrigerate; do not freeze. Subcutaneous injection. Monthly dosing. Dogs only. Single-use vial.

SQ injection: administer SQ in the dorsal neck or scruff. Administer monthly. Ensure correct dose per body weight. Store refrigerated (2–8°C); do not freeze. Bring to room temperature before injection. Single-use vial. If a dose is missed This product is given as a single dose or as part of a defined protocol. Contact your veterinarian if a scheduled administration was missed. Librela is given monthly — contact your veterinarian to reschedule.

Injection site reactions (most common — pain, swelling, licking). GI: vomiting, diarrhea, anorexia (uncommon). Neurological: paresis, ataxia (rare post-marketing — FDA pharmacovigilance). Renal: azotemia (rare). Anaphylaxis (very rare). Avoid in dogs with pre-existing neurological or renal disease.

For animals Dogs only. Post-marketing reports of neurological signs (paresis, ataxia) — avoid in dogs with pre-existing neurological or neuromuscular disease. Reduce dose or extend interval in renal impairment. — monitor renal parameters. Not for use in breeding, pregnant, or lactating dogs. Not approved for use in food-producing animals. For people handling this medication Administered by veterinary professionals only. No specific human precautions for caregivers beyond normal hygiene.

Contact your veterinarian. Monoclonal antibody overdose — contact vet for guidance. Unlikely to cause serious toxicity.